... What PARP Inhibitors Are Available?There are currently three FDA-approved PARP inhibitors available: Niraparib (Zejula) Rucaparib (Rubraca) Olaparib (Lynparza) Each can be given to women with or without BRCA gene mutations. ...
... Food and Drug Administration (FDA) approved a new combination targeted therapy called Avmapki Fakzynja Co-Pack, a combination of avutometinib and defactinib. These two oral drugs work together to block certain signals that help cancer cells grow and survive. ...
6 Ovarian Cancer Treatment Options
... Food and Drug Administration (FDA) approved a new combination targeted therapy called Avmapki Fakzynja Co-Pack, a combination of avutometinib and defactinib. These two oral drugs work together to block certain signals that help cancer cells grow and survive. ...
... It was approved in 2024 to treat platinum-resistant epithelial ovarian cancer, peritoneal cancer, or fallopian tube cancer.A newer targeted therapy called Avmapki Fakzynja Co-Pack, a combination of avutometinib and defactinib, was approved in 2025. It’s approved for adults with recurrent KRAS-mutated, low-grade serous ovarian cancer (LGSOC). ...
Recurrent Ovarian Cancer Explained
... It was approved in 2024 to treat platinum-resistant epithelial ovarian cancer, peritoneal cancer, or fallopian tube cancer.A newer targeted therapy called Avmapki Fakzynja Co-Pack, a combination of avutometinib and defactinib, was approved in 2025. It’s approved for adults with recurrent KRAS-mutated, low-grade serous ovarian cancer (LGSOC). ...
... The side effects were mostly minor and were similar to those seen with other PARP inhibitors. Whether people received Lynparza or not, they had a similar long-term quality of life. ...
... — National Institute on Aging Shared Decision Making in the Care of Patients With Cancer — ASCO Educational Book PARP Inhibitors and Ovarian Cancer — Ovarian Cancer Research Alliance Ovarian Cancer — Insights Into Platinum Resistance and Overcoming It — Medicina New Approaches for Targeting Platinum-Resistant Ovarian Cancer — Seminars in Cancer Biology ...
Platinum Resistance in Ovarian Cancer Treatment: What You Need To Know
... — National Institute on Aging Shared Decision Making in the Care of Patients With Cancer — ASCO Educational Book PARP Inhibitors and Ovarian Cancer — Ovarian Cancer Research Alliance Ovarian Cancer — Insights Into Platinum Resistance and Overcoming It — Medicina New Approaches for Targeting Platinum-Resistant Ovarian Cancer — Seminars in Cancer Biology ...
... (Rubraca), used in people with or without BRCA mutations PARP inhibitors are taken as pills and may cause nausea, fatigue, or low blood counts.Kinase InhibitorsKinase inhibitors target cancer cells with rare gene fusions like NTRK fusions or RET. ...
... CancerCare’s Co-Payment Assistance Foundation helps cover the costs of co-payments for cancer care. The Ovarian Cancer Research Alliance offers financial resources and support for people with ovarian cancer FundFinder is a web-based app developed by the Patient Access Network Foundation. ...
How To Get Ovarian Cancer Treatment Without Insurance
... CancerCare’s Co-Payment Assistance Foundation helps cover the costs of co-payments for cancer care. The Ovarian Cancer Research Alliance offers financial resources and support for people with ovarian cancer FundFinder is a web-based app developed by the Patient Access Network Foundation. ...
... Debulking Surgery (Cytoreduction) — City of Hope Carboplatin Injection — MedlinePlus Paclitaxel (With Polyoxyethylated Castor Oil) Injection — MedlinePlus Targeted Drug Therapy for Ovarian Cancer — American Cancer Society Bevacizumab Injection — MedlinePlus Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment — Obstetrics & Gynecology PARP ...
What You Need To Know About Epithelial Ovarian Cancer: Symptoms, Treatment, and Prognosis
... Debulking Surgery (Cytoreduction) — City of Hope Carboplatin Injection — MedlinePlus Paclitaxel (With Polyoxyethylated Castor Oil) Injection — MedlinePlus Targeted Drug Therapy for Ovarian Cancer — American Cancer Society Bevacizumab Injection — MedlinePlus Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment — Obstetrics & Gynecology PARP ...
... Common side effects of PARP inhibitors include nausea, vomiting, diarrhea, stomach pain, appetite problems, changes in the way things taste, anemia (low red blood cell counts), tiredness, and muscle or joint pain.If side effects bother you, talk to your cancer care team. They can help you find ways to better manage symptoms. ...
What To Expect From Ovarian Cancer Maintenance Treatment
... Common side effects of PARP inhibitors include nausea, vomiting, diarrhea, stomach pain, appetite problems, changes in the way things taste, anemia (low red blood cell counts), tiredness, and muscle or joint pain.If side effects bother you, talk to your cancer care team. They can help you find ways to better manage symptoms. ...
... PARP inhibitors are prescribed as targeted therapies for people with BRCA mutations. However, some PARP inhibitor therapies have been phased out in recent years and are no longer standard treatments.The U.S. ...
Join
